<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29121974</article-id><article-id pub-id-type="pmc">5679379</article-id><article-id pub-id-type="publisher-id">2275</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2275-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qurashi</surname><given-names>Inti</given-names></name><address><email>inti.qurashi@merseycare.nhs.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chaudhry</surname><given-names>Imran B.</given-names></name><address><email>imran.chaudhry@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Khoso</surname><given-names>Ameer B.</given-names></name><address><email>ameer.bukhsh@pill.org.pk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Farooque</surname><given-names>Sana</given-names></name><address><email>sana.farooque@pill.org.pk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>Steve</given-names></name><address><email>slane@liverpool.ac.uk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Husain</surname><given-names>Mohammad Omair</given-names></name><address><email>so_moo@hotmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8921-4942</contrib-id><name><surname>Chu</surname><given-names>Simon</given-names></name><address><email>schu@uclan.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sarginson</surname><given-names>Jane</given-names></name><address><email>jane.sarginson@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hamarani</surname><given-names>Munir</given-names></name><address><email>mhamirani@gmail.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Naqvi</surname><given-names>Haider A.</given-names></name><address><email>haider.naqvi@zu.edu.pk</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Razzaque</surname><given-names>Bushra</given-names></name><address><email>bushrazzaque@gmail.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Minhas</surname><given-names>Fareed A.</given-names></name><address><email>minhas.fa@gmail.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Yung</surname><given-names>Alison R.</given-names></name><address><email>alison.yung@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Deakin</surname><given-names>J. F. W.</given-names></name><address><email>bill.deakin@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Husain</surname><given-names>Nusrat</given-names></name><address><email>nusrat.husain@manchester.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Ashworth Research Centre, Mersey Care NHS Foundation Trust, Maghull, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution>Faculty of Medicine, Biology and Health, University of Manchester, </institution></institution-wrap>Manchester, UK </aff><aff id="Aff3"><label>3</label>Pakistan Institute of Living &#x00026; Learning, Karachi, Pakistan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8470</institution-id><institution-id institution-id-type="GRID">grid.10025.36</institution-id><institution>Institute of Translational Medicine, University of Liverpool, </institution></institution-wrap>Liverpool, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0489 8305</institution-id><institution-id institution-id-type="GRID">grid.451035.6</institution-id><institution>Manchester Mental Health and Social Care Trust, </institution></institution-wrap>Manchester, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2167 3843</institution-id><institution-id institution-id-type="GRID">grid.7943.9</institution-id><institution>School of Psychology, University of Central Lancashire, </institution></institution-wrap>Preston, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.413194.a</institution-id><institution>Abbasi Shaheed Hospital, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0571 5371</institution-id><institution-id institution-id-type="GRID">grid.413093.c</institution-id><institution>Ziauddin University, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff9"><label>9</label>Institute of Psychiatry &#x00026; WHO Collaborating Centre, Rawalpindi, Pakistan </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>524</elocation-id><history><date date-type="received"><day>26</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The at-risk mental state (ARMS) describes individuals at high risk of developing schizophrenia or psychosis. The use of antipsychotics in this population is not supported, because most individuals with ARMS are unlikely to develop psychosis. Anti-inflammatory treatments and polyunsaturated fatty acids (PUFAs) may have some beneficial effects in the treatment of ARMS. There have been no controlled clinical trials in which researchers have investigated the use of minocycline for ARMS and no trials involving PUFAs in combination with other proposed treatments. There is a need to find effective, tolerable and inexpensive interventions for individuals with ARMS that are available in high-, low- and middle-income countries.</p></sec><sec><title>Methods/design</title><p id="Par2">A 6-month intervention study of minocycline and/or omega-3 fatty acids added to treatment as usual (TAU) in patients with ARMS will be conducted in Pakistan using a randomised, placebo-controlled, double-blind factorial design. A total of 320 consenting patients with capacity will be recruited from the community, general practitioner clinics and psychiatric units. Allowing for a 25% dropout rate, we will recruit 59 completing participants into each study arm, and in total 236 will complete the study. We will determine whether the addition of minocycline and/or omega-3 fatty acids to TAU attenuates the rate of transition from ARMS to first-episode psychosis and improves symptoms and/or level of functioning in ARMS. We will also investigate whether any candidate risk factors, such as negative symptoms, influence treatment response in the ARMS group. The primary efficacy endpoint is conversion to psychotic disorder at 12&#x000a0;months after study entry. Analysis will be done according to the intention to treat principle using analysis of variance, chi-square tests and adjusted ORs to assess between-group differences. Cox regression analysis will be used to evaluate potential between-group differences in time to onset of psychosis.</p></sec><sec><title>Discussion</title><p id="Par3">The outcomes of this trial will provide evidence of the potential benefits of minocycline and PUFAs in the treatment of ARMS. Both minocycline and PUFAs are inexpensive, are readily available in low-/middle-income countries such as Pakistan, and if proven, may be safe and effective for treating individuals with ARMS.</p></sec><sec><title>Trial registration</title><p id="Par4">ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT02569307">NCT02569307</ext-link>. Registered on 3 October 2015.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-017-2275-y) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Minocycline</kwd><kwd>Omega-3 fatty acids</kwd><kwd>PUFA</kwd><kwd>At-risk mental state (ARMS)</kwd><kwd>Ultra-high risk (UHR) schizophrenia</kwd><kwd>Global mental health</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007123</institution-id><institution>Stanley Medical Research Institute</institution></institution-wrap></funding-source><award-id>14T-003</award-id><principal-award-recipient><name><surname>Qurashi</surname><given-names>Inti</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p id="Par20">The at-risk mental state (ARMS) describes individuals at increased risk of developing psychosis. Operationalised criteria have been developed to identify young persons with ARMS [<xref ref-type="bibr" rid="CR1">1</xref>]. Authors of a meta-analysis of 27 studies with a combined sample of 2500 subjects reported a transition to psychosis rate of 18% at 6&#x000a0;months, rising to 22% at 1&#x000a0;year [<xref ref-type="bibr" rid="CR2">2</xref>]. These studies were undertaken in Europe, the United States and Australia, and transition rates are likely to be higher, approaching 40%, in countries with less-established mental health care systems [<xref ref-type="bibr" rid="CR3">3</xref>]. Individuals who experience symptoms of ARMS are mostly help-seeking [<xref ref-type="bibr" rid="CR4">4</xref>], making it a critical period during which an intervention could be delivered to prevent conversion to psychosis, improve symptoms and reduce distress. Most of the disability develops before the onset of frank psychosis [<xref ref-type="bibr" rid="CR5">5</xref>], and earlier treatment of psychosis is linked to better outcomes [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par21">Interventions tested for ARMS include antipsychotics [<xref ref-type="bibr" rid="CR7">7</xref>] and cognitive behavioural therapy (CBT) [<xref ref-type="bibr" rid="CR8">8</xref>]. The use of antipsychotics in this population is not supported in, for example, national clinical guidance [<xref ref-type="bibr" rid="CR9">9</xref>], because a large proportion of individuals with ARMS are unlikely to develop psychosis. Furthermore, antipsychotics can cause side effects such as weight gain and other metabolic disturbances. An alternative approach is to explore the effectiveness of interventions within a clinically staged approach where the earlier in the course of illness treatment is offered, the safer and more tolerable it should be compared with treatments used later in the illness, whilst remaining effective in terms of remission and recovery rates [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par22">There is persuasive evidence to test the use of minocycline in individuals with ARMS. Authors of a meta-analysis of minocycline augmentation of antipsychotics pooled the results of four randomised controlled trials including young adults in the early phase of schizophrenia [<xref ref-type="bibr" rid="CR11">11</xref>] and found that minocycline was superior to placebo in reducing total scores on the Positive and Negative Syndrome Scale (PANSS), the PANSS negative subscale, and the PANSS general subscale. Minocycline was equivalent to placebo for all-cause discontinuation and for discontinuation because of adverse events. In addition, minocycline has a well-established effectiveness and safety profile in adolescents and young adults [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par23">Authors of three systematic reviews [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>] of interventions in the ARMS group found that antipsychotics, CBT and omega-3 fatty acids may have some effect on preventing or delaying the onset of psychosis, but all of these authors noted the need for ongoing research. A replication study of omega-3 fatty acids with a larger sample would be especially important, given that this treatment is relatively safe and has few health risks in a drug-na&#x000ef;ve population that could gain other potential benefits (such as improving cardiovascular status). In a subsequent study to determine whether omega-3 fatty acids in combination with a high-quality psychosocial intervention, cognitive behavioural case management (CBCM), was more effective than placebo plus CBCM, researchers did not detect a difference in transition to psychosis at 6&#x000a0;months [<xref ref-type="bibr" rid="CR16">16</xref>]. However, the lower-than-expected transition rate may have prevented a test of the main hypothesis, and the substantial symptomatic and functional improvement in both groups with the other treatments received (i.e., CBCM and antidepressants) is likely to have produced a ceiling effect beyond which omega-3 fatty acids, even if effective, could not be shown to confer additional benefits. Neither CBT nor CBCM is widely available in low- and middle-income countries, unlike nutritional supplements and antibiotics.</p><p id="Par24">In summary, there is a need to find effective, tolerable, inexpensive and safe interventions for individuals with ARMS, especially in view of the lack of availability of high-quality psychosocial interventions in low-/middle-income countries. Using a factorial design, we will compare placebo with minocycline and omega-3 fatty acids alone, as well as in combination, in the treatment of individuals with ARMS in Pakistan. The novel aspects of this trial include that (1) minocycline has not been tested as a treatment for individuals with ARMS, (2) minocycline and omega-3 fatty acids have not previously been tested in combination and potentially have additive/synergistic effects due to their modes of action, and (3) no drug trials for ARMS have been undertaken in Pakistan or similar low- and middle-income countries.</p></sec><sec id="Sec2"><title>Methods/design</title><sec id="Sec3"><title>Objectives</title><p id="Par25">The aim of the study is to evaluate the efficacy and tolerability of minocycline and omega-3 fatty acids in individuals with ARMS and specifically to determine whether the addition of minocycline and/or omega-3 fatty acids to treatment as usual (TAU) in an operationalised ARMS population in Pakistan (1) attenuates the rate or incidence of transition from ARMS to first-episode psychosis and (2) improves symptoms and/or level of functioning of individuals with ARMS. In addition, we will explore whether candidate risk factors, such as negative symptoms, socio-demographic characteristics and neurobiological variables, including metabolic parameters (such as erythrocyte membrane fatty acids and, where possible, cytokines), influence the transition to psychosis in the ARMS group.</p></sec><sec id="Sec4"><title>Study design</title><p id="Par26">We are conducting a 6-month intervention study of minocycline and/or omega-3 fatty acids added to TAU in patients with ARMS, using a randomised, placebo-controlled, double-blind factorial design. In practice, TAU in this population in Pakistan comprises no specific treatment, whether psychological or pharmacological. Participants will be randomly assigned to either (1) placebo, (2) minocycline, (3) omega-3 fatty acids or (4) minocycline and omega-3 fatty acids in combination. Blinding will be maintained because participants will receive equivalent numbers of tablets. In a factorial design the objective is generally not to compare arms with each other; instead, combinations of experimental conditions are compared. Each experimental condition in a factorial design represents a different treatment protocol. It allows a test of the possibility that the interventions being tested have additive or multiplicative benefits.</p></sec><sec id="Sec5"><title>Primary outcome measure</title><p id="Par27">The primary efficacy endpoint will be transition to psychotic disorder at 12&#x000a0;months after study entry. Transition is operationally defined using the positive symptom subscales in the Comprehensive Assessment of At Risk Mental States (CAARMS) [<xref ref-type="bibr" rid="CR17">17</xref>] as one of the following:<list list-type="bullet"><list-item><p id="Par28">Unusual thought content held with delusional intensity (global score 6) occurring several times or more per week (frequency and duration score&#x02009;&#x0003e;&#x02009;3)</p></list-item><list-item><p id="Par29">Non-bizarre ideas held with delusional conviction (global score 6) occurring several times or more per week (frequency and duration score&#x02009;&#x0003e;&#x02009;3)</p></list-item><list-item><p id="Par30">Perceptual abnormalities in any modality (global score&#x02009;&#x02265;&#x02009;5) occurring several times or more per week (frequency and duration score&#x02009;&#x0003e;&#x02009;3)</p></list-item><list-item><p id="Par31">Disorganised speech (global score&#x02009;&#x02265;&#x02009;5) occurring several times or more per week (frequency and duration score&#x02009;&#x0003e;&#x02009;4)</p></list-item></list>
</p></sec><sec id="Sec6"><title>Secondary outcome measures</title><p id="Par32">Secondary outcome measures are as follows:<list list-type="bullet"><list-item><p id="Par33">Change in severity of ARMS symptoms between entry (baseline) assessment and at 3, 6 and 12&#x000a0;months measured as difference in scores on the CAARMS</p></list-item><list-item><p id="Par34">Change in social and occupational functioning between baseline and 3, 6 and 12&#x000a0;months measured using the Social and Occupational Functioning Assessment Scale (SOFAS) [<xref ref-type="bibr" rid="CR18">18</xref>]</p></list-item><list-item><p id="Par35">Change in cognitive scores between baseline and 3, 6 and 12&#x000a0;months measured using the CogState battery [<xref ref-type="bibr" rid="CR19">19</xref>]</p></list-item><list-item><p id="Par36">Adverse effects of medications: proportion developing adverse effects as a function of severity</p></list-item><list-item><p id="Par37">Treatment with antipsychotic medication (from participant self-report and subsequent confirmation by clinician or by prescription evidence), because this is likely to correlate with conversion to psychosis</p></list-item><list-item><p id="Par38">Change in severity of depressive symptoms between entry at baseline and at 3, 6 and 12&#x000a0;months measured as the difference in scores on the Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) [<xref ref-type="bibr" rid="CR20">20</xref>]</p></list-item></list>
</p></sec><sec id="Sec7"><title>Sample size</title><p id="Par39">Sample size estimates are based on the expected transition rate to psychosis of 30%, and, on the basis of previous research, we expect to achieve a clinically meaningful reduction to 15% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] following treatment with minocycline and omega-3 fatty acids. With 80% power and at a 5% significance level, we will require a sample size of 59 per treatment arm to detect the expected difference. We are allowing for a drop-out rate of 25%, and in order to maintain 59 completing participants per arm, we will recruit 80 participants to each of the 4 trial arms. Therefore, we intend to recruit 320 participants in total.</p></sec><sec id="Sec8"><title>Study participants</title><sec id="Sec9"><title>Inclusion criteria</title><p id="Par40">Participants should fulfil all of the following criteria:<list list-type="bullet"><list-item><p id="Par41">Male or female individuals aged 16&#x02013;35 years</p></list-item><list-item><p id="Par42">Meet the criteria for ARMS using CAARMS operationalised intake criteria based on three groups (vulnerability, attenuated psychosis, or brief limited intermittent psychotic symptoms group)</p></list-item><list-item><p id="Par43">Assessed as competent to provide informed consent</p></list-item></list>
</p></sec><sec id="Sec10"><title>Exclusion criteria</title><p id="Par44">Individuals meeting any of the following criteria will be excluded:<list list-type="bullet"><list-item><p id="Par45">A history of psychotic illness (treated or untreated)</p></list-item><list-item><p id="Par46">IQ&#x02009;&#x0003c;&#x02009;70 and/or a history of learning disability</p></list-item><list-item><p id="Par47">Any pre-existing inflammatory conditions (e.g., rheumatoid arthritis)</p></list-item><list-item><p id="Par48">Organic brain disease (e.g., epilepsy)</p></list-item><list-item><p id="Par49">Previous treatment with an antipsychotic or mood-stabilising agent</p></list-item><list-item><p id="Par50">Prior history of intolerance or serious side effects (hepatotoxicity, photosensitivity, blood dyscrasia) of any of the tetracyclines or omega-3 fatty acids</p></list-item><list-item><p id="Par51">Concomitant penicillin therapy or concomitant anticoagulant therapy</p></list-item><list-item><p id="Par52">Active substance abuse (except nicotine or caffeine) or dependence within the last 3&#x000a0;months, according to <italic>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</italic>, criteria</p></list-item><list-item><p id="Par53">Treatment with warfarin or lamotrigine</p></list-item><list-item><p id="Par54">Current or previous treatment with tetracycline antibiotics or omega-3 fatty acids in the 3&#x000a0;months before study entry</p></list-item><list-item><p id="Par55">Current treatment with any anti-inflammatory medication</p></list-item><list-item><p id="Par56">Treatment with electroconvulsive therapy within the 12&#x000a0;weeks preceding the study</p></list-item><list-item><p id="Par57">Active expression of suicidal ideation or current aggressive/dangerous behaviour</p></list-item><list-item><p id="Par58">Relevant current or past hematologic, hepatic, renal, neurologic or other medical disorder that, in the opinion of the principal investigator (PI), might interfere with the study</p></list-item><list-item><p id="Par59">Pregnant or breastfeeding</p></list-item></list>
</p></sec><sec id="Sec11"><title>Withdrawal criteria</title><p id="Par60">Participants may be withdrawn from the research study for the following reasons:<list list-type="bullet"><list-item><p id="Par61">At their own request</p></list-item><list-item><p id="Par62">At the discretion of the investigator</p></list-item><list-item><p id="Par63">Participants who meet the exit criteria for transition to psychosis or develop mania</p></list-item><list-item><p id="Par64">Experiencing a serious adverse event or moderate to severe adverse drug reaction</p></list-item><list-item><p id="Par65">Participants meeting criteria for insufficient adherence, defined as either taking&#x02009;&#x0003c;&#x02009;75% of trial medication between assessment points at baseline, 1, 3 and 6&#x000a0;months or missing trial medications altogether for&#x02009;&#x02265;&#x02009;7&#x000a0;days in any period</p></list-item><list-item><p id="Par66">Becoming pregnant</p></list-item><list-item><p id="Par67">An antipsychotic being prescribed during the course of the study</p></list-item></list>
</p></sec></sec><sec id="Sec12"><title>Recruitment procedures</title><p id="Par68">Consenting patients with capacity will be recruited from the community, general practitioner clinics and psychiatric units in Pakistan.</p></sec><sec id="Sec13"><title>Instruments</title><p id="Par69">The following instruments will be used:<list list-type="bullet"><list-item><p id="Par70">
<italic>Prodromal Questionnaire-16 (PQ-16)</italic> [<xref ref-type="bibr" rid="CR23">23</xref>]: A brief self-report screening questionnaire that assesses the presence of attenuated psychotic symptoms, the PQ-16 is a reliable measure and correlates well with the CAARMS. It is a good screening instrument, and the low number of items makes it feasible to screen populations [<xref ref-type="bibr" rid="CR24">24</xref>].</p></list-item><list-item><p id="Par71">
<italic>SOFAS</italic> [<xref ref-type="bibr" rid="CR18">18</xref>]: A global rating of current functioning, this instrument focuses on social and occupational functioning that is independent of the overall severity of the individual&#x02019;s psychological symptoms [<xref ref-type="bibr" rid="CR25">25</xref>].</p></list-item><list-item><p id="Par72">
<italic>CAARMS</italic> [<xref ref-type="bibr" rid="CR17">17</xref>]: A semi-structured interview for the identification of individuals at increased risk of developing a first-episode psychotic disorder, it shows good to excellent concurrent, discriminant and predictive validity and excellent inter-rater reliability [<xref ref-type="bibr" rid="CR17">17</xref>].</p></list-item><list-item><p id="Par73">
<italic>CogState</italic> [<xref ref-type="bibr" rid="CR19">19</xref>]: This instrument comprises a number of individual tasks, each designed to test a specific area of cognition. The test battery is culturally neutral and user-friendly, and it covers all necessary cognitive domains. It comprises a range of computerised cognitive tasks able to measure baseline and change in all cognitive domains, and it shows good reliability and validity [<xref ref-type="bibr" rid="CR26">26</xref>].</p></list-item><list-item><p id="Par74">
<italic>MADRS</italic> [<xref ref-type="bibr" rid="CR20">20</xref>]: MADRS is an index of depression administered by a trained clinician who assigns a severity rating for symptoms of depression on the basis of a personal interview. The scale has demonstrated strong reliability, validity and sensitivity to change [<xref ref-type="bibr" rid="CR27">27</xref>].</p></list-item><list-item><p id="Par75">
<italic>Schizotypal Personality Questionnaire</italic> [<xref ref-type="bibr" rid="CR26">26</xref>]: A self-report measure of schizotypal personality disorder, this questionnaire incorporates nine schizotypal features. The scale consists of 74 yes/no items and has been shown to have strong reliability and validity [<xref ref-type="bibr" rid="CR28">28</xref>].</p></list-item></list>
</p><p id="Par76">We will use a structured rating scale to capture information on side effects. All the instruments have been translated into the Urdu language.</p></sec><sec id="Sec14"><title>Study procedure</title><p id="Par77">The schedule of visits and study procedures is outlined in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>)&#x000a0;and a completed SPIRIT checklist is given in Additional&#x000a0;file <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flowchart outlining the timetable of study procedures. <italic>CAARMS</italic> Comprehensive Assessment of At Risk Mental States, <italic>MADRS</italic> Montgomery-&#x000c5;sberg Depression Rating Scale, <italic>PQ-16</italic> Prodromal Questionnaire-16, <italic>SOFAS</italic> Social and Occupational Functioning Assessment Scale, <italic>SPQ</italic> Schizotypal Personality Questionnaire</p></caption><graphic xlink:href="13063_2017_2275_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Schedule of enrolment, interventions and assessments. <italic>CAARMS</italic> Comprehensive Assessment of At Risk Mental States, <italic>MADRS</italic> Montgomery-&#x000c5;sberg Depression Rating Scale, <italic>PQ-16</italic> Prodromal Questionnaire-16, <italic>SOFAS</italic> Social and Occupational Functioning Assessment Scale</p></caption><graphic xlink:href="13063_2017_2275_Fig2_HTML" id="MO2"/></fig>
</p><sec id="Sec15"><title>Consent visit</title><p id="Par78">A trained research assistant (RA) will visit potential participants at their homes or places convenient to them and confirm their suitability for inclusion by screening them using the inclusion/exclusion criteria, confirming consent, and pregnancy testing, if appropriate. The RA will arrange for a doctor to complete checklists for medical history, physical examination and haematological investigations. Participants will also complete the MADRS. Random assignment to the treatment arms will be stratified using the MADRS (total score cut-off&#x02009;&#x02265;&#x02009;21) because depressive symptoms may affect illness progression. A computer-generated random sequence based on a block randomised design (with varying block sizes of 2, 4, 6 and 8 in order to reduce predictability [<xref ref-type="bibr" rid="CR29">29</xref>]) will be administered by an independent third party until all study data are collected and verified. Participants, parents and those involved in administering interventions, assessing outcomes, data entry and/or data analysis will be blind to group assignments. All eligible participants will be randomised to one of the four study arms and allocated a unique identification number, and they will commence study drug treatment within 1&#x000a0;week of providing consent.</p></sec><sec id="Sec16"><title>Baseline visit</title><p id="Par79">The baseline clinical and neuropsychological measures will be completed. The participants will be given a 1-week supply of the study medication appropriate to the trial arm to which they have been randomised; a study information sheet explaining that they are in a clinical study; and the telephone numbers of the senior research clinicians and the clinical trial office, as well as the name of the local PI. In accordance with International Conference for Harmonisation good clinical practice guidelines, copies of all the above will be placed in the individuals&#x02019; records along with contact names and telephone numbers.</p></sec><sec id="Sec17"><title>Follow-up visits</title><p id="Par80">The first follow-up visit will occur after 1&#x000a0;week of treatment with the trial medication to check for safety and tolerability of the treatment initiated. At the first follow-up visit, the participant will also receive sufficient trial medication for the rest of the month. Follow-up visits will be conducted at 1-month intervals for the 6-month duration of the intervention and at a final visit 6&#x000a0;months after the end of the intervention (12&#x000a0;months after baseline). During the monthly visits, along with clinical and safety assessments, the participants will complete the MADRS, CAARMS and SOFAS assessments, and they will also receive their study medication. The RA will collect and deliver these to the participant. This will give the research team the opportunity to closely monitor the participant&#x02019;s physical and mental health, side effects and adherence (by pill count). Female participants with childbearing capacity taking part in the clinical trial will take a pregnancy test regularly. If they should become pregnant during the study, they will be withdrawn from the study.</p></sec><sec id="Sec18"><title>Final visit</title><p id="Par81">At this visit all clinical, neuropsychological and physical assessments will be completed. At all visits the participants&#x02019; cumulative clinical drug treatment will be updated from case notes.</p></sec></sec><sec id="Sec19"><title>Data management</title><p id="Par82">Data will be collected by trained RAs to maintain data confidentiality and anonymisation. A unique trial identity number will be used for participant data collection and processing. Trial documents (consent form, source documents, assessment tools, case report forms) in hard copies will be kept at the study site in locked file cabinets. Electronic data will be encrypted and password-protected. Backup electronic data will be saved at two places on a hard drive and an institution server. Access to data, both in hard copies and in electronic versions, will be restricted, and only designated persons as approved by the site PI will handle the data. A signed duty log will be used every time the data is accessed. After trial completion the PI will be responsible for data archiving and preservation. Any application for data sharing will also be handled by PI, and access to data will be granted with PI permission.</p></sec><sec id="Sec20"><title>Intervention</title><sec id="Sec21"><title>Minocycline</title><p id="Par83">Minocycline will be administered orally for a 6-month period. We have chosen to trial 200&#x000a0;mg because this is the dose used in previous trials in early-phase schizophrenia [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. A titration schedule will be used to minimise attrition. During the first week of the study, participants will receive a 100-mg capsule of minocycline (or matching placebo) daily. If this is tolerated, the participants will receive 200&#x000a0;mg of minocycline (or matching placebo) for the remaining intervention period. If a participant complains of side effects, the treating psychiatrist (blind to the intervention) will be allowed to omit up to the next two doses of medication and continue from the last prescribed dose. If, despite this, the participant is unable to tolerate an increased dose, the dose will be reduced by 50-mg decrements to a tolerable dose of minocycline or matching placebo.</p></sec><sec id="Sec22"><title>Omega-3 fatty acids</title><p id="Par84">Omega-3 fatty acids will be administered orally, and the daily dose of 1.2&#x000a0;g/day is based on trials in an ultra-high risk population [<xref ref-type="bibr" rid="CR32">32</xref>]. The active treatment will comprise 600-mg capsules containing concentrated marine fish oil. The proposed daily dose of two capsules will provide 720&#x000a0;mg of eicosapentaenoic acid and 480&#x000a0;mg of docosahexaenoic acid.</p></sec><sec id="Sec23"><title>Placebo</title><p id="Par85">Placebo capsules will be manufactured carefully to resemble the study drugs in appearance. The omega-3 fatty acid (in a soft-shell capsule) and minocycline (in a hard-shell capsule) will appear different because of their individual casing, but all participants will take one hard-shell and two soft-shell capsules, with placebo replacing the active comparator as required.</p></sec></sec><sec id="Sec24"><title>Research assistant training and inter-rater reliability</title><p id="Par86">RAs in Pakistan are trained in the assessment measures, and inter-rater reliability will be measured throughout the study by local PIs.</p></sec><sec id="Sec25"><title>Statistical analysis</title><p id="Par87">Initially the data will be described using summary statistics, and possible between-group differences will be assessed using analysis of variance (ANOVA) and chi-square tests. Analysis in all cases will be by intention to treat. All protocol violations and major deviations will be recorded as they occur and will be included in reports on trial findings. Because the primary outcome is categorical, logistic regression will be used to assess between-group differences, which will be described using ORs and corresponding 95% CIs. If between-group differences in demographic or other factors are observed, we will estimate adjusted ORs. Secondary and subgroup analyses will also use ANOVA and logistic regression along with other standard hypothesis-testing methods, including Cox regression to analyse potential between-group differences in time to onset of psychosis with non-completers and those who do not develop psychosis included as censored observations. A complete statistical analysis plan will be written prior to database lock and subsequently will be discussed and approved by the trial steering committee.</p></sec><sec id="Sec26"><title>Discontinuation</title><p id="Par88">The trial will end either when the study period ends or by the recommendation of the drug safety monitoring board if serious untoward events occur. For individual study participants, the intervention will be discontinued if there are adverse effects that warrant this or if the participant requests to exit the study.</p></sec><sec id="Sec27"><title>Adverse event reporting</title><p id="Par89">Adverse events, whether related to study conduct and intervention or not, will be recorded. If there is a serious adverse event, immediate notification of collaborating investigators and sites will be undertaken by the site PI. All essential and appropriate measures will be taken to ensure patient safety. If there are safety issues with the investigational medicines, immediate action will be taken across the whole study to prevent others from avoidable harm.</p></sec></sec><sec id="Sec28"><title>Discussion</title><p id="Par90">In Pakistan and other low-/middle-income countries, there is no specific TAU for individuals with ARMS. Minocycline and omega-3 fatty acids are inexpensive and widely available, and evidence suggests that they may be effective in delaying or preventing the onset of full psychosis. The compounds may be feasible and beneficial interventions for patients with ARMS, but there is a strong need to assess evidence of their efficacy. Should minocycline and/or omega-3 fatty acids prove to be effective, this will contribute to the growing body of evidence for treatment options in ARMS.</p></sec><sec id="Sec29"><title>Trial status</title><p id="Par91">This clinical trial was registered in October 2015 (ClinicalTrials.gov, NCT02569307), and participants are being recruited until the end of 2017.</p></sec></body><back><app-group><app id="App1"><sec id="Sec30"><title>Additional file</title><p id="Par98">
<media position="anchor" xlink:href="13063_2017_2275_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOCX 49&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ANOVA</term><def><p id="Par5">Analysis of variance</p></def></def-item><def-item><term>ARMS</term><def><p id="Par6">At-risk mental state</p></def></def-item><def-item><term>CAARMS</term><def><p id="Par7">Comprehensive Assessment of At Risk Mental States</p></def></def-item><def-item><term>CBCM</term><def><p id="Par8">Cognitive behavioural case management</p></def></def-item><def-item><term>CBT</term><def><p id="Par9">Cognitive behavioural therapy</p></def></def-item><def-item><term>MADRS</term><def><p id="Par10">Montgomery-&#x000c5;sberg Depression Rating Scale</p></def></def-item><def-item><term>PANSS</term><def><p id="Par11">Positive and Negative Syndrome Scale</p></def></def-item><def-item><term>PI</term><def><p id="Par12">Principal investigator</p></def></def-item><def-item><term>PQ-16</term><def><p id="Par13">Prodromal Questionnaire-16</p></def></def-item><def-item><term>PUFA</term><def><p id="Par14">Polyunsaturated fatty acid</p></def></def-item><def-item><term>RA</term><def><p id="Par15">Research assistant</p></def></def-item><def-item><term>SOFAS</term><def><p id="Par16">Social and Occupational Functioning Assessment Scale</p></def></def-item><def-item><term>SPIRIT</term><def><p id="Par17">Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item><def-item><term>SPQ</term><def><p id="Par18">Schizotypal Personality Questionnaire</p></def></def-item><def-item><term>TAU</term><def><p id="Par19">Treatment as usual</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2275-y) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. Paul Stephenson for his critical review of the manuscript prior to submission. This study represents independent research funded by the Stanley Medical Research Institute (SMRI). The views expressed are those of the authors and not necessarily those of SMRI.</p><sec id="FPar1"><title>Funding</title><p id="Par92">This study is funded by the Stanley Research Medical Institute (SMRI; grant number 14&#x000a0;T-003). SMRI played no role in the design of the study.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par93">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>IQ is the chief investigator of the study. IQ, IBC and NH conceived of the idea for the study, contributed to the design of the study and drafted the manuscript. SC contributed to the study design, advised on quantitative aspects of the study and drafted the manuscript. ABK and SF are involved in recruitment and data collection and assisted with the manuscript. SL contributed to the design of the study and provided statistical advice. MOH, MH, HAN, BR, FAM and JFWD contributed to the design of the study. JS contributed to the design of the study and advised on biomarkers. ARY contributed to the design of the study and advised on assessments and outcome measures. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par94">Institutional review board (IRB) approval has been obtained from the ethics committee of the Karachi Medical and Dental College and Dow University of Health Sciences, Pakistan. Written consent will be obtained from each participant prior to any trial-related data collection.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par95">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par96">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par97">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>AR</given-names></name><name><surname>McGorry</surname><given-names>PD</given-names></name><name><surname>McFarlane</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Monitoring and care of young people at incipient risk of psychosis</article-title><source>Schizophr Bull</source><year>1996</year><volume>22</volume><fpage>283</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1093/schbul/22.2.283</pub-id><pub-id pub-id-type="pmid">8782287</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusar-Poli</surname><given-names>P</given-names></name><name><surname>Bonoldi</surname><given-names>I</given-names></name><name><surname>Yung</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk</article-title><source>Arch Gen Psychiatry</source><year>2012</year><volume>69</volume><fpage>220</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.1472</pub-id><pub-id pub-id-type="pmid">22393215</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>AR</given-names></name><name><surname>Yuen</surname><given-names>HP</given-names></name><name><surname>Berger</surname><given-names>G</given-names></name><etal/></person-group><article-title>Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?</article-title><source>Schizophr Bull</source><year>2007</year><volume>33</volume><fpage>673</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbm015</pub-id><pub-id pub-id-type="pmid">17404389</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>AR</given-names></name><name><surname>McGorry</surname><given-names>PD</given-names></name></person-group><article-title>The prodromal phase of first-episode psychosis: past and current conceptualizations</article-title><source>Schizophr Bull</source><year>1996</year><volume>22</volume><issue>2</issue><fpage>353</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/schbul/22.2.353</pub-id><pub-id pub-id-type="pmid">8782291</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname><given-names>H</given-names></name></person-group><article-title>Modelling the early course of schizophrenia</article-title><source>Schizophr Bull</source><year>2003</year><volume>29</volume><fpage>325</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a007008</pub-id><pub-id pub-id-type="pmid">14552507</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Lockwood</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review</article-title><source>Arch Gen Psychiatry</source><year>2005</year><volume>62</volume><fpage>975</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.62.9.975</pub-id><pub-id pub-id-type="pmid">16143729</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGlashan</surname><given-names>TH</given-names></name><name><surname>Zipursky</surname><given-names>RB</given-names></name><name><surname>Perkins</surname><given-names>D</given-names></name><etal/></person-group><article-title>Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><fpage>790</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1176/ajp.2006.163.5.790</pub-id><pub-id pub-id-type="pmid">16648318</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>AP</given-names></name><name><surname>Stewart</surname><given-names>SL</given-names></name><name><surname>French</surname><given-names>P</given-names></name><etal/></person-group><article-title>Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics</article-title><source>Early Interv Psychiatry</source><year>2011</year><volume>5</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7893.2010.00254.x</pub-id><pub-id pub-id-type="pmid">21272272</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence (NICE)</collab></person-group><source>Psychosis and schizophrenia in children and young people: recognition and management. NICE Clinical Guidance 155</source><year>2013</year><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGorry</surname><given-names>PD</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name><name><surname>Amminger</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Intervention in individuals at ultra-high risk for psychosis: a review and future directions</article-title><source>J Clin Psychiatry</source><year>2009</year><volume>70</volume><fpage>1206</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.4088/JCP.08r04472</pub-id><pub-id pub-id-type="pmid">19573499</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oya</surname><given-names>K</given-names></name><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name></person-group><article-title>Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Hum Psychopharmacol</source><year>2014</year><volume>29</volume><fpage>483</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/hup.2426</pub-id><pub-id pub-id-type="pmid">25087702</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name></person-group><article-title>Safety of doxycycline and minocycline: a systematic review</article-title><source>Clin Ther</source><year>2005</year><volume>27</volume><fpage>1329</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2005.09.005</pub-id><pub-id pub-id-type="pmid">16291409</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafford</surname><given-names>MR</given-names></name><name><surname>Jackson</surname><given-names>H</given-names></name><name><surname>Mayo-Wilson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Early interventions to prevent psychosis: systematic review and meta-analysis</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>f185</fpage><pub-id pub-id-type="doi">10.1136/bmj.f185</pub-id><pub-id pub-id-type="pmid">23335473</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Gaag</surname><given-names>M</given-names></name><name><surname>Smit</surname><given-names>F</given-names></name><name><surname>Bechdolf</surname><given-names>A</given-names></name><etal/></person-group><article-title>Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12&#x000a0;month and longer-term follow-ups</article-title><source>Schizophr Res</source><year>2013</year><volume>149</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2013.07.004</pub-id><pub-id pub-id-type="pmid">23870806</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>PJ</given-names></name></person-group><article-title>Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis</article-title><source>Psychol Med</source><year>2014</year><volume>44</volume><fpage>449</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1017/S0033291713000354</pub-id><pub-id pub-id-type="pmid">23521867</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGorry</surname><given-names>PD</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name><name><surname>Markulev</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of &#x003c9;-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial</article-title><source>JAMA Psychiat</source><year>2017</year><volume>74</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.2902</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>AR</given-names></name><name><surname>Yuen</surname><given-names>HP</given-names></name><name><surname>McGorry</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States</article-title><source>Aust N Z J Psychiatry</source><year>2005</year><volume>39</volume><fpage>964</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1080/j.1440-1614.2005.01714.x</pub-id><pub-id pub-id-type="pmid">16343296</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>HH</given-names></name><name><surname>Skodol</surname><given-names>AE</given-names></name><name><surname>Lave</surname><given-names>TR</given-names></name></person-group><article-title>Revising axis V for DSM-IV: a review of measures of social functioning</article-title><source>Am J Psychiatry</source><year>1992</year><volume>149</volume><fpage>1148</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1176/ajp.149.8.1119-a</pub-id><pub-id pub-id-type="pmid">1386964</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Cysique</surname><given-names>L</given-names></name><etal/></person-group><article-title>Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex</article-title><source>Arch Clin Neuropsychol</source><year>2000</year><volume>24</volume><fpage>165</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1093/arclin/acp010</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Asberg</surname><given-names>M</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change</article-title><source>Br J Psychiatry</source><year>1979</year><volume>134</volume><fpage>382</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id><pub-id pub-id-type="pmid">444788</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ising</surname><given-names>HK</given-names></name><name><surname>Smit</surname><given-names>F</given-names></name><name><surname>Veling</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial</article-title><source>Psychol Med</source><year>2015</year><volume>45</volume><fpage>1435</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1017/S0033291714002530</pub-id><pub-id pub-id-type="pmid">25330734</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ising</surname><given-names>HK</given-names></name><name><surname>Kraan</surname><given-names>TC</given-names></name><name><surname>Rietdijk</surname><given-names>J</given-names></name><etal/></person-group><article-title>Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial</article-title><source>Schizophr Bull</source><year>2016</year><volume>42</volume><fpage>1243</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbw018</pub-id><pub-id pub-id-type="pmid">26994397</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loewy</surname><given-names>RL</given-names></name><name><surname>Bearden</surname><given-names>CE</given-names></name><name><surname>Johnson</surname><given-names>JK</given-names></name><etal/></person-group><article-title>The Prodromal Questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes</article-title><source>Schizophr Res</source><year>2005</year><volume>79</volume><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2005.03.007</pub-id><pub-id pub-id-type="pmid">16276559</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ising</surname><given-names>HK</given-names></name><name><surname>Veling</surname><given-names>W</given-names></name><name><surname>Loewy</surname><given-names>RL</given-names></name><etal/></person-group><article-title>The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population</article-title><source>Schizophr Bull</source><year>2012</year><volume>38</volume><fpage>1288</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs068</pub-id><pub-id pub-id-type="pmid">22516147</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morosini</surname><given-names>PL</given-names></name><name><surname>Magliano</surname><given-names>L</given-names></name><name><surname>Brambilla</surname><given-names>L</given-names></name><etal/></person-group><article-title>Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning</article-title><source>Acta Psychiatr Scand</source><year>2000</year><volume>101</volume><issue>4</issue><fpage>323</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10782554</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrzak</surname><given-names>RH</given-names></name><name><surname>Olver</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>T</given-names></name><etal/></person-group><article-title>A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia</article-title><source>J Clin Exp Neuropsychol</source><year>2009</year><volume>31</volume><fpage>848</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1080/13803390802592458</pub-id><pub-id pub-id-type="pmid">19142774</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Turnbull</surname><given-names>CD</given-names></name><name><surname>Strickland</surname><given-names>R</given-names></name><etal/></person-group><article-title>The Montgomery-&#x000c5;sberg Depression Scale: reliability and validity</article-title><source>Acta Psychiatr Scand</source><year>1986</year><volume>73</volume><fpage>544</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1986.tb02723.x</pub-id><pub-id pub-id-type="pmid">3751660</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raine</surname><given-names>A</given-names></name></person-group><article-title>The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R</article-title><source>Schizophr Bull</source><year>1991</year><volume>17</volume><fpage>555</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/schbul/17.4.555</pub-id><pub-id pub-id-type="pmid">1805349</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efird</surname><given-names>J</given-names></name></person-group><article-title>Blocked randomization with randomly selected block sizes</article-title><source>Int J Environ Res Public Health</source><year>2011</year><volume>8</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.3390/ijerph8010015</pub-id><pub-id pub-id-type="pmid">21318011</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>I</given-names></name><name><surname>Hallak</surname><given-names>J</given-names></name><name><surname>Husain</surname><given-names>N</given-names></name><etal/></person-group><article-title>Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment</article-title><source>J Psychopharmacol</source><year>2012</year><volume>26</volume><fpage>1185</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/0269881112444941</pub-id><pub-id pub-id-type="pmid">22526685</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Minocycline supplementation for the treatment of negative symptoms in early-phase schizophrenia: a double-blind randomized controlled trial</article-title><source>Schizophr Res</source><year>2014</year><volume>153</volume><fpage>169</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2014.01.011</pub-id><pub-id pub-id-type="pmid">24503176</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amminger</surname><given-names>GP</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>MR</given-names></name><name><surname>Schl&#x000f6;gelhofer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>7934</fpage><pub-id pub-id-type="doi">10.1038/ncomms8934</pub-id><pub-id pub-id-type="pmid">26263244</pub-id></element-citation></ref></ref-list></back></article>